176 related articles for article (PubMed ID: 29377788)
1. Factors Influencing Transition to Shisheh (Methamphetamine) among Young People Who Use Drugs in Tehran: A Qualitative Study.
Noroozi A; Malekinejad M; Rahimi-Movaghar A
J Psychoactive Drugs; 2018; 50(3):214-223. PubMed ID: 29377788
[TBL] [Abstract][Full Text] [Related]
2. Investigating the sequential patterns of methamphetamine use initiation in Iran.
Sarani EM; Ahmadi J; Oji B; Mahi-Birjand M; Bagheri N; Bazrafshan A; Manshadi MD; Yaghoubi S; Dezhkam A; Khatami M; Abdollahpour-Alitappeh M
Subst Abuse Treat Prev Policy; 2020 Jul; 15(1):52. PubMed ID: 32727512
[TBL] [Abstract][Full Text] [Related]
3. Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.
Palmer A; Scott N; Dietze P; Higgs P
Harm Reduct J; 2020 Feb; 17(1):14. PubMed ID: 32106854
[TBL] [Abstract][Full Text] [Related]
4. Profile of People Who Inject Drugs in Tehran, Iran.
Amin-Esmaeili M; Rahimi-Movaghar A; Gholamrezaei M; Razaghi EM
Acta Med Iran; 2016 Dec; 54(12):793-805. PubMed ID: 28120592
[TBL] [Abstract][Full Text] [Related]
5. Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: the first report from Iran.
Mehrjerdi ZA; Abarashi Z; Noroozi A; Arshad L; Zarghami M
Int J STD AIDS; 2014 May; 25(6):420-7. PubMed ID: 24287028
[TBL] [Abstract][Full Text] [Related]
6. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
Sun R; Sauda TH; Hoopsick RA
Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
[TBL] [Abstract][Full Text] [Related]
7. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.
Fredericksen RJ; Baker R; Sibley A; Estadt AT; Colston D; Mixson LS; Walters S; Bresett J; Levander XA; Leichtling G; Davy-Mendez T; Powell M; Stopka TJ; Pho M; Feinberg J; Ezell J; Zule W; Seal D; Cooper HLF; Whitney BM; Delaney JAC; Crane HM; Tsui JI
Harm Reduct J; 2024 Apr; 21(1):74. PubMed ID: 38561753
[TBL] [Abstract][Full Text] [Related]
8. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
Kinner SA; Degenhardt L
Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
[TBL] [Abstract][Full Text] [Related]
9. From opiates to methamphetamine: building new harm reduction responses in Jakarta, Indonesia.
Rigoni R; Woods S; Breeksema JJ
Harm Reduct J; 2019 Dec; 16(1):67. PubMed ID: 31829253
[TBL] [Abstract][Full Text] [Related]
10. The risk environments of people who use drugs accessing two harm reduction centers in Tehran, Iran: A qualitative study.
Bastani P; Marshall BDL; Rahimi-Movaghar A; Noroozi A
Int J Drug Policy; 2019 Jan; 63():90-96. PubMed ID: 30513474
[TBL] [Abstract][Full Text] [Related]
11. How do drug market changes affect characteristics of injecting initiation and subsequent patterns of drug use? Findings from a cohort of regular heroin and methamphetamine injectors in Melbourne, Australia.
Horyniak D; Stoové M; Degenhardt L; Aitken C; Kerr T; Dietze P
Int J Drug Policy; 2015 Jan; 26(1):43-50. PubMed ID: 25304048
[TBL] [Abstract][Full Text] [Related]
12. 'Ice epidemic'? Trends in methamphetamine use from three Victorian surveillance systems.
Lim MS; Cogger S; Quinn B; Hellard ME; Dietze PM
Aust N Z J Public Health; 2015 Apr; 39(2):194-5. PubMed ID: 25559677
[No Abstract] [Full Text] [Related]
13. A qualitative study of methamphetamine initiation in Cape Town, South Africa.
Hobkirk AL; Watt MH; Myers B; Skinner D; Meade CS
Int J Drug Policy; 2016 Apr; 30():99-106. PubMed ID: 26614737
[TBL] [Abstract][Full Text] [Related]
14. Service providers' experience of methamphetamine and the portrayal of the 'ice epidemic' in remote Australia.
Cartwright K; Tait RJ
Aust J Rural Health; 2019 Feb; 27(1):83-87. PubMed ID: 30693985
[TBL] [Abstract][Full Text] [Related]
15. Transition to injection amongst opioid users in Iran: implications for harm reduction.
Malekinejad M; Vazirian M
Int J Drug Policy; 2012 Jul; 23(4):333-7. PubMed ID: 21996166
[TBL] [Abstract][Full Text] [Related]
16. Use of gelatine capsules for application of methamphetamine: a new harm reduction approach.
Mravčík V; Skařupová K; Orlíková B; Zábranský T; Karachaliou K; Schulte B
Int J Drug Policy; 2011 Mar; 22(2):172-3. PubMed ID: 21242079
[TBL] [Abstract][Full Text] [Related]
17. A qualitative exploration of the factors associated with initiation to methamphetamine use in Iran.
Shahbazi Sighaldeh S; Zarghami F; Shahryari A; Mohammadinia A; Ebrahimi M; Jorjani T; Hamrah MS; Charkazi A
BMC Public Health; 2020 Nov; 20(1):1773. PubMed ID: 33228618
[TBL] [Abstract][Full Text] [Related]
18. Substance-use and sexual harm reduction strategies of methamphetamine-using men who have sex with men and inject drugs.
Wilkerson JM; Noor SW; Breckenridge ED; Adeboye AA; Rosser BR
AIDS Care; 2015; 27(8):1047-54. PubMed ID: 25837492
[TBL] [Abstract][Full Text] [Related]
19. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work.
Davitadze A; Meylakhs P; Lakhov A; King EJ
Harm Reduct J; 2020 Dec; 17(1):98. PubMed ID: 33298081
[TBL] [Abstract][Full Text] [Related]
20. A qualitative study of methamphetamine initiation among Chinese male users: Patterns and policy implications.
Liu L; Chui WH; Chai X
Int J Drug Policy; 2018 Dec; 62():37-42. PubMed ID: 30359871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
